Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

William F. Regine*, Kathryn Winter, Ross A. Abrams, Howard Safran, Ivan L. Kessel, Yuhchyau Chen, James A. Fugazzi, Eric D. Donnelly, Thomas A. DiPetrillo, Samir Narayan, John P. Plastaras, Rakesh Gaur, Guila Delouya, John H. Suh, Joshua E. Meyer, Michael G. Haddock, Mukund S. Didolkar, Gilbert D.A. Padula, David Johnson, John P. HoffmanChristopher H. Crane

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor individualized management in this disease setting. This secondary analysis assessed the prognostic value of postresection CA19-9 and surgical margin status (SMS) in predicting patterns of disease recurrence. Methods and materials: This multicenter cooperative trial included participants who were enrolled as patients at oncology treatment sites in the United States and Canada. The study included 451 patients analyzable for SMS, of whom 385 were eligible for postresection CA19-9 analysis. Postresection CA19-9 was analyzed at cut points of 90, 180, and continuously. Patterns of disease recurrence included local/regional recurrence (LRR) and distant failure (DF). Multivariable analyses included treatment, tumor size, and nodal status. To adjust for multiple comparisons, a P value of ≤.01 was considered statistically significant and >.01 to ≤.05 to be a trend. Results: For CA19-9, 132 (34%) patients were Lewis antigen–negative (no CA19-9 expression), 200 (52%) had levels <90, and 220 (57%) had levels <180. A total of 188 patients (42%) had negative margins, 152 (34%) positive, and 111 (25%) unknown. On univariate analysis, CA19-9 cut at 90 was associated with increases in LRR (trend) and DF. Results were similar at the 180 cut point. SMS was not associated with an increase in LRR on univariate or multivariate analyses. On multivariable analysis, CA19-9 ≥ 90 was associated with increased LRR and DF. Results were similar at the 180 cut point. Conclusions: In this prospective evaluation, postresection CA19-9 was a significant predictor of both LRR and DF, whereas SMS was not. These findings support consideration of adjuvant radiation therapy dose intensification in patients with elevated postresection CA19-9.

Original languageEnglish (US)
Pages (from-to)154-162
Number of pages9
JournalAdvances in Radiation Oncology
Volume3
Issue number2
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704'. Together they form a unique fingerprint.

  • Cite this

    Regine, W. F., Winter, K., Abrams, R. A., Safran, H., Kessel, I. L., Chen, Y., Fugazzi, J. A., Donnelly, E. D., DiPetrillo, T. A., Narayan, S., Plastaras, J. P., Gaur, R., Delouya, G., Suh, J. H., Meyer, J. E., Haddock, M. G., Didolkar, M. S., Padula, G. D. A., Johnson, D., ... Crane, C. H. (2018). Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Advances in Radiation Oncology, 3(2), 154-162. https://doi.org/10.1016/j.adro.2018.01.003